Published in Pflugers Arch on November 06, 2013
Vasopressin and disruption of calcium signalling in polycystic kidney disease. Nat Rev Nephrol (2015) 0.89
Autophagy in renal diseases. Pediatr Nephrol (2015) 0.85
Metformin Inhibits Cyst Formation in a Zebrafish Model of Polycystin-2 Deficiency. Sci Rep (2017) 0.75
TOR signaling in growth and metabolism. Cell (2006) 35.29
Growing roles for the mTOR pathway. Curr Opin Cell Biol (2005) 11.66
Volume progression in polycystic kidney disease. N Engl J Med (2006) 7.16
The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J (2008) 6.32
Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med (2010) 5.50
Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int (2003) 4.84
The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci U S A (2006) 4.56
Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med (2010) 4.36
Co-assembly of polycystin-1 and -2 produces unique cation-permeable currents. Nature (2001) 4.28
Somatic inactivation of Pkd2 results in polycystic kidney disease. Cell (1998) 3.84
Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int (2009) 3.66
PKD1 interacts with PKD2 through a probable coiled-coil domain. Nat Genet (1997) 3.58
Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Lancet (1999) 3.32
LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiol (Oxf) (2009) 2.94
Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol (2004) 2.69
Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care (2011) 2.54
Sirolimus reduces polycystic liver volume in ADPKD patients. J Am Soc Nephrol (2008) 2.26
Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease. J Am Soc Nephrol (2006) 2.21
Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant (2005) 2.09
Structural and molecular basis of the assembly of the TRPP2/PKD1 complex. Proc Natl Acad Sci U S A (2009) 1.84
Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1. J Am Soc Nephrol (2010) 1.70
Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. Proc Natl Acad Sci U S A (2011) 1.69
Metformin-associated lactic acidosis in an intensive care unit. Crit Care (2008) 1.66
Coordinate expression of the autosomal dominant polycystic kidney disease proteins, polycystin-2 and polycystin-1, in normal and cystic tissue. Am J Pathol (1999) 1.59
Polycystin-1 regulates extracellular signal-regulated kinase-dependent phosphorylation of tuberin to control cell size through mTOR and its downstream effectors S6K and 4EBP1. Mol Cell Biol (2009) 1.58
Identification of gene mutations in autosomal dominant polycystic kidney disease through targeted resequencing. J Am Soc Nephrol (2012) 1.57
Autosomal dominant polycystic kidney disease: comprehensive mutation analysis of PKD1 and PKD2 in 700 unrelated patients. Hum Mutat (2012) 1.45
Polycystin-1 expression in PKD1, early-onset PKD1, and TSC2/PKD1 cystic tissue. Kidney Int (1999) 1.42
The tuberous sclerosis proteins regulate formation of the primary cilium via a rapamycin-insensitive and polycystin 1-independent pathway. Hum Mol Genet (2008) 1.30
Family history of renal disease severity predicts the mutated gene in ADPKD. J Am Soc Nephrol (2009) 1.23
Novel assay of metformin levels in patients with type 2 diabetes and varying levels of renal function: clinical recommendations. Diabetes Care (2010) 1.23
Identification of mutations in the duplicated region of the polycystic kidney disease 1 gene (PKD1) by a novel approach. Am J Hum Genet (1997) 1.21
A polycystin-2 (TRPP2) dimerization domain essential for the function of heteromeric polycystin complexes. EMBO J (2010) 1.18
Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD). Nephrol Dial Transplant (2009) 1.16
Novel conditionally immortalized human proximal tubule cell line expressing functional influx and efflux transporters. Cell Tissue Res (2009) 1.14
Mammalian target of rapamycin and the kidney. I. The signaling pathway. Am J Physiol Renal Physiol (2012) 1.11
Polycystin-2 activation by inositol 1,4,5-trisphosphate-induced Ca2+ release requires its direct association with the inositol 1,4,5-trisphosphate receptor in a signaling microdomain. J Biol Chem (2010) 1.10
Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease. J Am Soc Nephrol (2012) 1.10
Emerging evidence of a link between the polycystins and the mTOR pathways. Pathogenetics (2009) 1.09
mTOR inhibitors in polycystic kidney disease. N Engl J Med (2010) 1.09
Mammalian target of rapamycin and the kidney. II. Pathophysiology and therapeutic implications. Am J Physiol Renal Physiol (2012) 1.07
Lack of a laterality phenotype in Pkd1 knock-out embryos correlates with absence of polycystin-1 in nodal cilia. Differentiation (2005) 1.07
Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: What is the appropriate serum level? Am J Transplant (2010) 1.03
Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease. Kidney Int (2010) 1.02
Mechanism-based therapeutics for autosomal dominant polycystic kidney disease: recent progress and future prospects. Nephron Clin Pract (2011) 1.00
Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease. Am J Physiol Renal Physiol (2009) 0.98
Novel mechanism of reducing tumourigenesis: upregulation of the DNA repair enzyme OGG1 by rapamycin-mediated AMPK activation and mTOR inhibition. Eur J Cancer (2010) 0.98
Polycystin-1 and polycystin-2 are both required to amplify inositol-trisphosphate-induced Ca2+ release. Cell Calcium (2012) 0.89
Increased prevalence of polycystic kidney disease type 2 among elderly polycystic patients. Am J Kidney Dis (2000) 0.88
Activation of AMP-activated kinase as a strategy for managing autosomal dominant polycystic kidney disease. Med Hypotheses (2009) 0.85
Mutation detection in the repeated part of the PKD1 gene. Am J Hum Genet (1997) 0.84
Do mTOR inhibitors still have a future in ADPKD? Nat Rev Nephrol (2010) 0.82
PKD2 gene mutation analysis in Korean autosomal dominant polycystic kidney disease patients using two-dimensional gene scanning. Clin Genet (2006) 0.82
Batch RNAi selector: a standalone program to predict specific siRNA candidates in batches with enhanced sensitivity. Comput Methods Programs Biomed (2007) 0.81
Randomized intervention studies in human polycystic kidney and liver disease. J Am Soc Nephrol (2010) 0.80
Autosomal dominant polycystic kidney disease and mTOR inhibitors: the narrow road between hope and disappointment. Nephrol Dial Transplant (2010) 0.80
mTOR inhibitors and autosomal dominant polycystic kidney disease. N Engl J Med (2011) 0.79
Mechanism of activation of AMPK and upregulation of OGG1 by rapamycin in cancer cells. Oncotarget (2011) 0.78
Characterisation and expression of the PKD-1 protein, polycystin, in renal and extrarenal tissues. Kidney Int (1999) 0.77
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Measuring glomerular filtration rate using 51Cr-EDTA: body surface area normalization before or after Bröchner-Mortensen correction? Nucl Med Commun (2014) 2.02
The tumor suppressor eIF3e mediates calcium-dependent internalization of the L-type calcium channel CaV1.2. Neuron (2007) 1.89
Structural and molecular basis of the assembly of the TRPP2/PKD1 complex. Proc Natl Acad Sci U S A (2009) 1.84
Targeting Bcl-2-IP3 receptor interaction to reverse Bcl-2's inhibition of apoptotic calcium signals. Mol Cell (2008) 1.71
Modification of store-operated channel coupling and inositol trisphosphate receptor function by 2-aminoethoxydiphenyl borate in DT40 lymphocytes. J Biol Chem (2001) 1.68
Induction of Ca²+-driven apoptosis in chronic lymphocytic leukemia cells by peptide-mediated disruption of Bcl-2-IP3 receptor interaction. Blood (2010) 1.68
The BH4 domain of Bcl-2 inhibits ER calcium release and apoptosis by binding the regulatory and coupling domain of the IP3 receptor. Proc Natl Acad Sci U S A (2009) 1.61
Phosphorylation of inositol 1,4,5-trisphosphate receptors by protein kinase B/Akt inhibits Ca2+ release and apoptosis. Proc Natl Acad Sci U S A (2008) 1.59
Regulation of InsP3 receptor activity by neuronal Ca2+-binding proteins. EMBO J (2003) 1.58
A dual role for Ca(2+) in autophagy regulation. Cell Calcium (2011) 1.56
The N-terminal Ca2+-independent calmodulin-binding site on the inositol 1,4,5-trisphosphate receptor is responsible for calmodulin inhibition, even though this inhibition requires Ca2+. Mol Pharmacol (2004) 1.56
Identification, characterization, and localization of a novel kidney polycystin-1-polycystin-2 complex. J Biol Chem (2002) 1.56
Role of endoplasmic reticulum depletion and multidomain proapoptotic BAX and BAK proteins in shaping cell death after hypericin-mediated photodynamic therapy. FASEB J (2006) 1.53
Subcellular distribution of the inositol 1,4,5-trisphosphate receptors: functional relevance and molecular determinants. Biol Cell (2004) 1.53
Pannexins, distant relatives of the connexin family with specific cellular functions? Bioessays (2009) 1.50
Association of mutation position in polycystic kidney disease 1 (PKD1) gene and development of a vascular phenotype. Lancet (2003) 1.47
Genetic testing in the assessment of living related kidney donors at risk of autosomal dominant polycystic kidney disease. Transplantation (2015) 1.44
Functional characterization of mammalian inositol 1,4,5-trisphosphate receptor isoforms. Biophys J (2004) 1.43
Up-regulation of inositol 1,4,5-trisphosphate receptor type 1 is responsible for a decreased endoplasmic-reticulum Ca2+ content in presenilin double knock-out cells. Cell Calcium (2006) 1.40
Functional characterization of GATA3 mutations causing the hypoparathyroidism-deafness-renal (HDR) dysplasia syndrome: insight into mechanisms of DNA binding by the GATA3 transcription factor. Hum Mol Genet (2007) 1.36
Identification of an N-terminal glycogen synthase kinase 3 phosphorylation site which regulates the functional localization of polycystin-2 in vivo and in vitro. Hum Mol Genet (2006) 1.36
Caspase-3-induced truncation of type 1 inositol trisphosphate receptor accelerates apoptotic cell death and induces inositol trisphosphate-independent calcium release during apoptosis. J Biol Chem (2004) 1.36
Haploinsufficiency of Pkd2 is associated with increased tubular cell proliferation and interstitial fibrosis in two murine Pkd2 models. Nephrol Dial Transplant (2006) 1.33
Intracellular Ca2+ storage in health and disease: a dynamic equilibrium. Cell Calcium (2010) 1.32
Genotype-phenotype studies in nail-patella syndrome show that LMX1B mutation location is involved in the risk of developing nephropathy. Eur J Hum Genet (2005) 1.32
Endoplasmic-reticulum calcium depletion and disease. Cold Spring Harb Perspect Biol (2011) 1.31
Paracrine signaling through plasma membrane hemichannels. Biochim Biophys Acta (2012) 1.28
Regulation of inositol 1,4,5-trisphosphate-induced Ca2+ release by reversible phosphorylation and dephosphorylation. Biochim Biophys Acta (2008) 1.27
Functional analysis of PKD1 transgenic lines reveals a direct role for polycystin-1 in mediating cell-cell adhesion. J Am Soc Nephrol (2003) 1.26
Renal phenotype in Lowe Syndrome: a selective proximal tubular dysfunction. Clin J Am Soc Nephrol (2008) 1.24
The epithelial Mg2+ channel transient receptor potential melastatin 6 is regulated by dietary Mg2+ content and estrogens. J Am Soc Nephrol (2006) 1.23
The IP(3) receptor-mitochondria connection in apoptosis and autophagy. Biochim Biophys Acta (2010) 1.22
Bigenic heterozygosity and the development of steroid-resistant focal segmental glomerulosclerosis. Nephrol Dial Transplant (2008) 1.22
Identification and functional analysis of two Ca2+-binding EF-hand motifs in the B"/PR72 subunit of protein phosphatase 2A. J Biol Chem (2003) 1.21
OCRL controls trafficking through early endosomes via PtdIns4,5P₂-dependent regulation of endosomal actin. EMBO J (2011) 1.21
Thimerosal stimulates Ca2+ flux through inositol 1,4,5-trisphosphate receptor type 1, but not type 3, via modulation of an isoform-specific Ca2+-dependent intramolecular interaction. Biochem J (2004) 1.19
A polycystin-2 (TRPP2) dimerization domain essential for the function of heteromeric polycystin complexes. EMBO J (2010) 1.18
Release of gliotransmitters through astroglial connexin 43 hemichannels is necessary for fear memory consolidation in the basolateral amygdala. FASEB J (2012) 1.17
Selective inhibition of Cx43 hemichannels by Gap19 and its impact on myocardial ischemia/reperfusion injury. Basic Res Cardiol (2012) 1.17
Ins(1,4,5)P3 receptor-mediated Ca2+ signaling and autophagy induction are interrelated. Autophagy (2011) 1.16
Phosphorylation of IP3R1 and the regulation of [Ca2+]i responses at fertilization: a role for the MAP kinase pathway. Development (2006) 1.14
The secretory pathway Ca2+/Mn2+-ATPase 2 is a Golgi-localized pump with high affinity for Ca2+ ions. J Biol Chem (2005) 1.12
Identification and functional characterization of an N-terminal oligomerization domain for polycystin-2. J Biol Chem (2008) 1.11
The protein phosphatase 2A phosphatase activator is a novel peptidyl-prolyl cis/trans-isomerase. J Biol Chem (2005) 1.11
Polycystin-2 activation by inositol 1,4,5-trisphosphate-induced Ca2+ release requires its direct association with the inositol 1,4,5-trisphosphate receptor in a signaling microdomain. J Biol Chem (2010) 1.10
Intramolecular loop/tail interactions are essential for connexin 43-hemichannel activity. FASEB J (2010) 1.10
Endothelin B receptor blockade accelerates disease progression in a murine model of autosomal dominant polycystic kidney disease. J Am Soc Nephrol (2007) 1.10
TRPM8-independent menthol-induced Ca2+ release from endoplasmic reticulum and Golgi. J Biol Chem (2006) 1.09
The Ca2+/Mn2+ pumps in the Golgi apparatus. Biochim Biophys Acta (2004) 1.09
SPCA1 pumps and Hailey-Hailey disease. Biochem Biophys Res Commun (2004) 1.08
Mutation analysis and clinical implications of von Willebrand factor-cleaving protease deficiency. Kidney Int (2003) 1.07
The C terminus of Bax inhibitor-1 forms a Ca2+-permeable channel pore. J Biol Chem (2011) 1.07